GAMMA Investing LLC Buys 52,711 Shares of BioNTech SE (NASDAQ:BNTX)

GAMMA Investing LLC boosted its stake in BioNTech SE (NASDAQ:BNTX) by 5,710.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 53,634 shares of the company’s stock after purchasing an additional 52,711 shares during the quarter. GAMMA Investing LLC’s holdings in BioNTech were worth $4,884,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its stake in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares during the period. Quintet Private Bank Europe S.A. raised its holdings in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE purchased a new stake in shares of BioNTech in the 4th quarter valued at about $90,000. Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech in the 4th quarter valued at about $137,000. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at about $168,000. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BNTX. JPMorgan Chase & Co. decreased their price objective on BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. Morgan Stanley decreased their price objective on BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group began coverage on BioNTech in a report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price objective on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Finally, Leerink Partners set a $112.00 price objective on BioNTech in a report on Monday, June 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.25.

BioNTech Stock Performance

NASDAQ:BNTX opened at $106.89 on Wednesday. The stock has a 50-day simple moving average of $99.87 and a two-hundred day simple moving average of $108.36. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $25.70 billion, a PE ratio of -50.90 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.90 earnings per share. Analysts forecast that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.